Something went wrong

We encountered an unexpected error, we encourage you to try again later.

We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

PP-UNP-USA-5796
Order samples Unable to confirm your eligibility

Unfortunately, your registration is incomplete and we are unable to confirm your eligibility for sample ordering.

To gain access please enter your professional information within your account.

Open your account We're here to help

Should you need further support updating your account information, please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples
Thank you for expressing interest in Pfizer samples. Currently there are no samples available to order. Samples renew periodically, we encourage you to check back soon.
 We're here to help

Should you have additional questions please contact PfizerPro customer service.

Representatives are available:
Monday-Friday 8:00am to 9:00pm Eastern time

Call 1 (800) 505-4426

​​​​​​​PP-UNP-USA-5796
Order samples

All samples available online to you are included below. Availability is updated periodically.

PP-UNP-USA-5796
Important Notice

Savings cards will be shipped with Product Samples, if applicable.

Signature

Use your mouse, finger, or stylus to sign below.

Legal Notice

I certify that I am a licensed prescriber, eligible to request and receive the drug samples listed in the quantities indicated. I am also confirming that these samples will be used exclusively for the medical treatment of my patients in conformity with all relevant state and/or local prescribing and dispensing requirements. My signature will also serve as confirmation of my receipt of these medications, if delivered by a company representative, or my intention to acknowledge them upon delivery to my medical office if shipped via common carrier. I understand that these samples cannot be sold, traded, bartered returned for credit or utilized to seek or obtain reimbursement.

Your order has been placed

We have received your order and are getting it ready

More to explore Patient assistance

Download available co-pay cards and patient savings offers across select Pfizer products.

Explore patient assistance Loading Vaccines

Find out more about the diseases, treatments and prevention methods that are impacted by our Pfizer Vaccine portfolio.

Explore Vaccines Loading
PP-UNP-USA-5796
Leave ordering?

Changes you have made will not be saved.

This site is intended for U.S. healthcare professionals.

For patient resources and support click HERE

Menu

Close

Sign InLog OutTherapy AreasProductsOrder VaccinesOrder SamplesOrderMaterialsCo-pay Cards & Patient Savings OffersRequest SamplesHospital ProductsVaccinesPatient AssistancePfizer Oncology TogetherPfizer RxPathwaysPfizer Dermatology Patient AccessExplore ContentEventsMaterialsVideosContact

Menu

Close

HomeAbout NGENLAEfficacy & SafetyEfficacy &
SafetyPhase 3 Main Study + SafetyPhase 3 OLE Study + SafetyPhase 2 Study + SafetyDosingDosingDosingAdministrationMyNgenla PlanIGF-1 MonitoringAccess & SupportAccess &
SupportUS Formulary CoverageAccessPatient SupportDevice Training EducationRequest a Pfizer RepDownloadable MaterialsVideos
Prescribing InformationIndication Patient Site
Access & Support

NGENLA has the broadest preferred commercial coverage in the US of any pediatric long-acting growth hormone (LAGH).1 Pfizer is here to assist you in supporting your patients as they get started on treatment.

US Formulary CoverageAccessPatient SupportDevice Training EducationRequest a Pfizer RepThe Pfizer Bridge Program® can support your patients through their NGENLA journey in many ways InsuranceAssist with understanding the insurance process CopayCopay assistance for eligible patients* ShippingArrange for the first shipment from the pharmacy and address issues that may lead to pharmacy delays or treatment interruptions Device trainingDevice training education by an experienced nurse
Submit a complete Patient Enrollment Form to the Pfizer Bridge Program to get started
Enrollment in the Pfizer Bridge Program is not required to access NGENLASign up patients via enrollment form 

Submit an enrollment form via fax at 1‑800-479-2562 or efax at WWW.PATIENTSUPPORTNOW.ORG and enter patient support code 8004792562

Download a Patient
Enrollment Form LoadingSign up patients via HCP portal

Complete the Patient Enrollment Form digitally via the Pfizer Bridge Program HCP Portal

Pfizer Bridge Program HCP Portal
Loading

If the patient and/or caregiver is unavailable to sign the enrollment form, you can still submit and direct them to the below website to complete their consents: https://pfizerbridgeprogram.com/BridgeProvider/s/esign-ondemand. The Pfizer Bridge Program will also make an outreach to the patient to obtain any missing required consents.

Pfizer FAS will communicate with you when action is needed for your patients enrolled in the Pfizer Bridge Program.FAS, field access specialist.TERMS AND CONDITIONS
By using this offer for the NGENLA Copay Program, you acknowledge that you currently meet the eligibility criteria and will comply with the terms and conditions described below:
  • Eligible patients with commercial prescription drug insurance coverage for NGENLA may pay as little $0 per prescription fill. Patient out of pocket expense will vary. The value of this offer is limited to annual benefit of $1,000-$8,000. Once a patient reaches the annual maximum benefit, patient is responsible for paying the remaining monthly out of pocket costs.
  • Patients are not eligible for this offer if they are enrolled in a state or federally funded insurance program, including but not limited to Medicare, Medicaid, TRICARE, Veteran Affairs health care, a state prescription drug assistance program, or the Government Health Insurance Plan available in Puerto Rico (formerly known as “La Reforma de Salud”).
  • Patients must have private insurance. Offer is not valid for cash paying patients.
  • This offer is not valid when the entire cost of your prescription drug is eligible to be reimbursed by your private insurance plan or other private health or pharmacy benefit programs.
  • You must deduct the value of this offer from any reimbursement request submitted to your private insurance plan, either directly by you or on your behalf.
  • You are responsible for reporting use of the NGENLA Copay Program to any private insurer, health plan, or other third party who pays for or reimburses any part of the prescription filled using the NGENLA Copay Card as may be required. You should not use the NGENLA Copay Card if your insurer or health plan prohibits use of manufacturer copay cards.
  • This copay card is not valid where prohibited by law.
  • The benefit under the NGENLA Copay Program is offered to, and intended for the sole benefit of, eligible patients and may not be transferred to or utilized for the benefit of third parties, including, without limitation, third party payers, pharmacy benefit managers, or the agents of either.
  • Third party payers, pharmacy benefit managers, or the agents of either are prohibited from assisting patients with enrolling in the NGENLA Copay Program.
  • Copay card cannot be combined with any other external savings, free trial or similar offer for the specified prescription (including any program offered by a third party payer or pharmacy benefit manager, or an agent of either, that adjusts patient cost-sharing obligations, through arrangements that may be referred to as “accumulator adjustment” or “copay maximizer” programs).
  • Some health insurers or pharmacy benefit managers (or their agents) may have established accumulator adjustment or copay maximizer programs based on the availability of support under the NGENLA Copay Program and/or exclude the financial assistance provided under the offer NGENLA Copay Program from counting towards patient deductibles or out-of-pocket cost limitations.
  • Patients subject to an accumulator adjustment or copay maximizer program are not eligible for this offer. Since you may be unaware whether you are subject to an accumulator adjustment or copay maximizer program when you enroll in this offer, Pfizer may monitor program utilization data and reserves the right to discontinue, reduce, or otherwise modify this offer at any time without notice.
  • Copay card will be accepted only at participating pharmacies.
  • If your pharmacy does not participate, you may be able to submit a request for a rebate in connection with this offer at www.pfizerbridgecopay.com.
  • This copay card is not health insurance.
  • Offer good only in the U.S. (excluding Puerto Rico, the U.S. Virgin Islands, and Guam).
  • Copay card is limited to 1 per person during this offering period and is not transferable.
  • A copay card may not be redeemed more than once per 21 days per patient.
  • No other purchase is necessary.
  • Data related to your redemption of the copay card may be collected, analyzed, and shared with Pfizer, for market research and other purposes related to assessing Pfizer’s programs. Data shared with Pfizer will be aggregated and de-identified; it will be combined with data related to other copay card redemptions and will not identify you.
  • Pfizer reserves the right to rescind, revoke, or amend this offer without notice.
  • Offer expires 12/31/2026.
  • For questions regarding the offer, please call 1-800-645-1280, visit www.ngenla.com, or write NGENLA Copay Program, 430 Mountain Avenue, Suite 105, New Providence, NJ 07974
Reference:Data on file. Pfizer Inc., New York, NY.Access and SupportDownloadable Materials

Convenient resources to support your patients as they begin treatment with NGENLA.

Learn More Loading

To report an adverse event, please call 1-800-438-1985

Pfizer for Professionals 1-800-505-4426

This site is intended only for U.S. healthcare professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

© 2026 Pfizer Inc. All rights reserved.

PP-SMT-USA-0672
You are now leaving PfizerPro You are now leaving a Pfizer-operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.PP-SMT-USA-0592
INDICATIONNgenla is indicated for the treatment of pediatric patients aged 3 years and older who have growth failure due to an inadequate secretion of endogenous growth hormone.
IMPORTANT SAFETY INFORMATIONCONTRAINDICATIONS
Ngenla is contraindicated in patients with:
  • Acute critical illness after open heart surgery, abdominal surgery or multiple accidental trauma, or acute respiratory failure due to the risk of increased mortality with somatropin
  • Hypersensitivity to somatrogon-ghla or any of the excipients in Ngenla
  • Closed epiphyses
  • Active malignancy due to the risk of malignancy progression
  • Active proliferative or severe non-proliferative diabetic retinopathy
  • Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea or have severe respiratory impairment due to the sudden risk of death
WARNINGS AND PRECAUTIONS
Increased Mortality in Patients with Acute Critical Illness: Increased mortality in patients with acute critical illness due to complications following open heart surgery, abdominal surgery, or multiple accidental trauma, or those with acute respiratory failure has been reported with somatropin.Severe Hypersensitivity: Severe systemic hypersensitivity reactions including anaphylactic reactions and angioedema have been reported with somatropin. Inform patients and/or caregivers that such reactions are possible, and to seek prompt medical attention if allergic reaction occurs.Increased Risk of Neoplasms: There is an increased risk of malignancy progression with somatropin treatment in patients with active malignancy. Any preexisting malignancy should be inactive, and its treatment should be completed, prior to instituting therapy. In childhood cancer survivors treated with radiation to the brain/head for their first neoplasm and developed subsequent GHD and were treated with somatropin, an increased risk of a second neoplasm has been reported. Monitor patients with a history of GHD secondary to an intracranial neoplasm for progression or recurrence of the tumor. Children with certain rare genetic causes of short stature have an increased risk of developing malignancies. Monitor for development of neoplasms. Monitor patients for increased growth or potential malignant changes of preexisting nevi. Advise patients and/or caregivers to report marked changes in behavior, onset of headaches, vision disturbances, and/or changes in skin pigmentation or changes in the appearance of preexisting nevi. Glucose Intolerance and Diabetes Mellitus: Treatment with growth hormone may decrease insulin sensitivity, particularly at higher doses. New-onset type 2 diabetes mellitus has been reported. Patients with undiagnosed pre-diabetes and diabetes mellitus may experience worsened glycemic control and become symptomatic. Monitor glucose levels periodically in all patients receiving Ngenla, especially in those with risk factors for diabetes mellitus. The doses of antidiabetic agents may require adjustment when Ngenla is initiated. Intracranial Hypertension (IH): Has been reported in patients treated with somatropin, usually within 8 weeks of treatment initiation. Perform fundoscopic examination prior to initiation of treatment and periodically thereafter. If papilledema is identified, evaluate the etiology, and treat the underlying cause before initiating Ngenla. Temporarily discontinue Ngenla in patients with evidence of IH. If IH is confirmed, restart Ngenla at a lower dose after IH signs and symptoms have resolved. Fluid Retention: May occur during Ngenla therapy. Clinical manifestations of fluid retention are usually transient and dose dependent. Hypoadrenalism: Patients receiving growth hormone therapy who have or are at risk for pituitary hormone deficiencies may be at risk for reduced serum cortisol levels and/or unmasking of central (secondary) hypoadrenalism. Patients treated with glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in their maintenance or stress doses following initiation of Ngenla. Monitor patients with known hypoadrenalism for reduced serum cortisol levels and/or need for glucocorticoid dose increases. Hypothyroidism: Undiagnosed/untreated hypothyroidism may prevent an optimal response to Ngenla. Central (secondary) hypothyroidism may first become evident or worsen during treatment with growth hormone therapy. Monitor thyroid function periodically and appropriately initiate or adjust thyroid hormone replacement therapy. Slipped Capital Femoral Epiphysis: Slipped capital femoral epiphysis may occur more frequently in patients undergoing rapid growth. Slipped capital femoral epiphysis may lead to osteonecrosis. Cases of slipped capital femoral epiphysis with or without osteonecrosis have been reported in pediatric patients with short stature receiving somatropin. Evaluate pediatric patients with the onset of a limp or complaints of persistent hip or knee pain for slipped capital femoral epiphysis and osteonecrosis and manage accordingly. Progression of Preexisting Scoliosis: Monitor patients with a history of scoliosis for disease progression. Pancreatitis: Cases of pancreatitis have been reported in patients receiving somatropin. The risk may be greater in pediatric patients compared with adults. Consider pancreatitis in patients who develop persistent severe abdominal pain. Lipoatrophy: May occur if Ngenla is administered at the same site over a long period of time. Rotate injection sites to reduce this risk. Sudden Death in Pediatric Patients with Prader-Willi Syndrome: There have been reports of sudden death after initiating therapy with somatropin in pediatric patients with Prader‑Willi syndrome who had one or more of the following risk factors: severe obesity, history of upper airway obstruction or sleep apnea, or unidentified respiratory infection. Male patients with one or more of these factors may be at greater risk. Ngenla is not indicated for the treatment of pediatric patients who have growth failure due to genetically confirmed Prader‑Willi syndrome. Laboratory Tests: Serum levels of phosphorus, alkaline phosphatase, and parathyroid hormone may increase with NGENLA therapy. Monitor as appropriate. ADVERSE REACTIONS
Adverse reactions reported in ≥5% of patients treated with Ngenla are injection site reactions, nasopharyngitis, headache, pyrexia, anemia, cough, vomiting, hypothyroidism, abdominal pain, rash, and oropharyngeal pain. Health care providers should supervise the first injection and provide appropriate training and instruction for the proper use of all NGENLA devices.DRUG INTERACTIONS
Glucocorticoids: Patients treated with glucocorticoid for hypoadrenalism may require an increase in their maintenance or stress doses.Cytochrome P450-Metabolized Drugs: Ngenla may alter the clearance. Monitor carefully.Oral Estrogen: Patients receiving oral estrogen replacement may require higher Ngenla dosages.Insulin and/or Other Antihyperglycemic Agents: Dose adjustment of insulin and/or antihyperglycemic agent may be required.
INDICATION
Ngenla is indicated for the treatment of pediatric patients aged 3 years and older who have growth failure due to an inadequate secretion of endogenous growth hormone.